

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): November 30, 2018**

**BRAIN SCIENTIFIC INC.**  
(Exact Name of Registrant as Specified in Charter)

**Nevada**  
(State or Other Jurisdiction  
of Incorporation)

**333-209325**  
(Commission  
File Number)

**81-0876714**  
(I.R.S. Employer  
Identification No.)

**205 East 42<sup>nd</sup> Street, 14<sup>th</sup> Floor**  
**New York, New York 10017**  
(Address of Principal Executive Offices) (Zip Code)

**Registrant's telephone number, including area code: (646) 388-3788**

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).  
Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 7.01 Regulation FD Disclosure.**

On November 30, 2018, Brain Scientific Inc. (the “Company”) issued a press release announcing that it intends to introduce its NeuroCap and NeuroEEG™, the portable, clinical-grade and FDA-cleared diagnostic devices held by MemoryMD, Inc., the Company’s wholly-owned subsidiary, to epilepsy specialists at the 2018 American Epilepsy Society (AES) Annual Meeting taking place in New Orleans from November 30 - December 4, 2018. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01 and in Exhibit 99.1 of Item 9.01 is being furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1 of Item 9.01.

**Item 9.01 Financial Statements and Exhibits**

*(d) Exhibits.*

The exhibit listed in the following Exhibit Index is furnished as part of this Form 8-K:

<b>Exhibit No.</b>	<b>Document</b>
99.1	<a href="#"><u>Press Release</u></a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 30, 2018

**BRAIN SCIENTIFIC INC.**

By: /s/ Boris Goldstein  
Name: Boris Goldstein  
Title: Chairman of the Board

## **Brain Scientific To Introduce Two FDA Cleared Devices At American Epilepsy Society Annual Meeting**

NEW YORK, Nov 30, 2018 – Brain Scientific Inc. (OTC:BRSF) (“Brain Scientific” or “Company”), a medical device company combining brain analysis software with wireless sensor technologies for teleneurology solutions, today announced it will introduce NeuroCap and NeuroEEG™, the portable, clinical-grade and FDA-cleared diagnostic devices held by MemoryMD, Inc., the Company’s wholly-owned subsidiary, to epilepsy specialists at the 2018 American Epilepsy Society (AES) Annual Meeting taking place in New Orleans from November 30 - December 4, 2018.

Brain Scientific will be unveiling the NeuroCap and NeuroEEG diagnostic devices alongside its selling partner MVAP Medical Supplies. MVAP is an industry leading supplier selling sleep, electroencephalograms (“EEG”) and electromyography (“EMG”) products to over 18,000 healthcare organizations and providers across the United States.

EEG devices are used in acute care clinics and emergency departments to record electrical activity. However, a shortage of technicians skilled in their use and the complexity of the equipment, have significantly limited the use of EEGs in the US healthcare system. This has led to re-admission problems which add an estimated approximately \$17.4 billion in annual spending by Medicare.

The Company believes that NeuroCap and NeuroEEG satisfy an unmet need in the current EEG standard. The two complementary diagnostic devices are designed to be portable, convenient and administered by any healthcare worker, rather than specialized neurological technicians. Clinics using NeuroCap and NeuroEEG have shortened the administration time of EEG testing by nearly half, and cut costs compared to traditional EEG systems.

“We are thrilled to be unveiling our FDA-cleared NeuroCap and NeuroEEG at the largest gathering on epilepsy in the world,” stated Irina Nazarova, Marketing Director of Brain Scientific. “The AES will be attended by professionals in academia, clinical practice and industry, all of whom will be introduced to our smart devices expected to make teleneurology easily available to patients.”

Brain Scientific welcomes AES attendees to visit MVAP booth #317 and learn how NeuroCap and NeuroEEG can help improve patient care.

### **About Brain Scientific**

Brain Scientific is a healthcare technology company developing next generation teleneurology solutions. The Company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about our corporate strategy, devices or for investor relations please visit [www.brainscientific.com](http://www.brainscientific.com) or email us at [info@brainscientific.com](mailto:info@brainscientific.com).

### **About the 2018 AES Annual Meeting**

The 72nd Annual Meeting of the American Epilepsy Society is 2018's premier national gathering of healthcare professionals who treat and research epilepsy. Visit <https://meeting.aesnet.org> for more information.

---

## **Forward-Looking Statements**

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek” or “project” or the negative of these words or other variations on these words or comparable terminology. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand its business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.

## **Contact Brain Scientific**

Irina Nazarova, Marketing Director at [nazarova@memorymd.com](mailto:nazarova@memorymd.com)